Download PDF
Pneumologie 2009; 63(9): 497-507
DOI: 10.1055/s-0029-1214908
Übersicht

© Georg Thieme Verlag Stuttgart · New York

Lungenbeteiligung bei systemischer Sklerodermie

Lung Impairment in Systemic SclerosisH.  Knoop1 , U.  Arinir1 , A.  Kreuter2 , J.  W.  Walther1 , G.  Schultze-Werninghaus1 , G.  Rohde1
  • 1Medizinische Klinik III – Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH, Klinikum der Ruhr-Universität Bochum (Direktor: Prof. Dr. G. Schultze-Werninghaus)
  • 2Klinik für Dermatologie und Allergologie, St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum (Direktor: Prof. Dr. P. Altmeyer)
Further Information

Publication History

eingereicht 29.5.2009

akzeptiert 4.6.2009

Publication Date:
25 August 2009 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Unter dem Oberbegriff Sklerodermie werden heterogene Autoimmunerkrankungen zusammengefasst, die verdickte, sklerotische Hautläsionen gemein haben. Die Sklerodermie zählt zum Formenkreis der Kollagenosen. Die systemische Form der Sklerodermie wird als Progressive Systemische Sklerose (PSS) oder systemische Sklerodermie (SSc) bezeichnet. Die Lungenbeteiligung bei SSc in Form von interstitieller Lungenerkrankung (ILD) und pulmonal-arterieller Hypertonie (PAH) ist eine der häufigsten Manifestationen der Erkrankung. Das Ziel dieser Arbeit besteht darin, einen Überblick über die Formen des Lungenbefalls bei SSc mit besonderem Augenmerk auf die interstitiellen Lungenerkrankungen zu geben – unter Berücksichtigung der bisher identifizierten pathogenetischen Mechanismen und der Therapieoptionen.

Abstract

Scleroderma is a generic term for autoimmunological diseases having thickened sclerotic skin lesions in common. Scleroderma belongs to a group of connective tissue diseases. The systemic form of scleroderma is called progressive systemic sclerosis (PSS) or systemic sclerosis (SSc). Lung impairments, namely interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), are one of the most common manifestations in SSc. This article summarises the forms of lung impairment in SSc with special emphasis on interstitial lung diseases and draws attention to the so far identified pathogenetic mechanisms and the presently accepted therapeutic options.

Literatur

  • 1 Lorenz J. Pneumologie. Stuttgart; Thieme Verlag 2004: 379-381
    Google Scholar
  • 2 Gintrac M. Note sur la sclerodermie.  Rev Med Chir Paris. 1847;  2 263-281
    PubMedGoogle Scholar
  • 3 LeRoy E C, Black C, Fleischmajer R. et al . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.  J Rheumatol. 1988;  15 202-205
    PubMedGoogle Scholar
  • 4 LeRoy E C, Medsger Jr T A. Criteria for the classification of early systemic sclerosis.  J Rheumatol. 2001;  28 1573-1576
    PubMedGoogle Scholar
  • 5 Johnson S R, Feldman B M, Hawker G A. Classification criteria for systemic sclerosis subsets.  J Rheumatol. 2007;  34 1855-1863
    PubMedGoogle Scholar
  • 6 Black C M. The Aetiopathogenesis Of Systemic Sclerosis: Thick Skin – Thin Hypotheses. The Parkes Weber Lecture 1994.  JR Coll Physicians London. 1995;  29 119-130
    PubMedGoogle Scholar
  • 7 Arbeitsgemeinschaft dermatologische Forschung . Klinik der progressiven systemischen Sklerodermie (PSS).  Hautarzt. 1986;  37 320-324
    PubMedGoogle Scholar
  • 8 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee . Preliminary criteria for the classification of systemic sclerosis (scleroderma).  Arthritis Rheum. 1980;  23 581-590
    CrossrefPubMedGoogle Scholar
  • 9 Benan M, Hande I, Gul O. The natural course of progressive systemic sclerosis patients with interstitial lung involvement.  Clin Rheumatol. 2007;  26 349-354
    CrossrefPubMedGoogle Scholar
  • 10 Clements P, Lachenbruch P, Seibold J R. et al . Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.  J Rheumatol. 1995;  22 1281-1285
    PubMedGoogle Scholar
  • 11 Verrecchia F, Laboureau J, Verola O. et al . Skin involvement in scleroderma – where histological and clinical scores meet.  Rheumatology. 2007;  46 833-841
    CrossrefPubMedGoogle Scholar
  • 12 Rodnan G P, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma.  Arthritis Rheum. 1979;  22 130-140
    CrossrefPubMedGoogle Scholar
  • 13 Czirjak L, Nagy Z, Aringer M. et al . The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis.  Ann Rheum Dis. 2007;  66 966-969
    CrossrefPubMedGoogle Scholar
  • 14 Steen V D, Oddis C V, Conte C G. et al . Incidence of systemic sclerosis in allegheny county, Pennsylvania: A twenty-year study of hospital-diagnosed cases, 1963 – 1982.  Arthritis & Rheum. 1997;  40 441-445
    PubMedGoogle Scholar
  • 15 Mayes M D. Scleroderma epidemiology [review].  Rheum Dis Clin North Am. 2003;  29 239-254
    CrossrefPubMedGoogle Scholar
  • 16 Vonk M C, Broers B, Heijdra Y F. et al . Systemic sclerosis and its pulmonary complications in the Netherlands an epidemiological study.  Ann Rheum Dis. 2009;  68 961-965
    CrossrefPubMedGoogle Scholar
  • 17 Mayes M D, Lacey Jr J V, Beebe-Dimmer J. et al . Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.  Arthritis Rheum. 2003;  48 2246-2255
    CrossrefPubMedGoogle Scholar
  • 18 Walker U A, Tyndall A, Czirjak L. et al . Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database.  Ann Rheum Dis. 2007;  66 754-763
    CrossrefPubMedGoogle Scholar
  • 19 Hunzelmann N, Genth E, Krieg T. et al . The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement.  Rheumatology (Oxford). 2008;  47 1185-1192
    CrossrefPubMedGoogle Scholar
  • 20 Arnett F C, Cho M, Chatterjee S. et al . Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts.  Arthritis Rheum. 2001;  44 1359-1362
    CrossrefPubMedGoogle Scholar
  • 21 Shahin A A. Pulmonary involvement in systemic sclerosis.  Treat Respir Med. 2006;  5 429-436
    CrossrefPubMedGoogle Scholar
  • 22 Pontifex E K, Hill C L, Roberts-Thomsen P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study.  Ann Rheum Dis. 2007;  66 551-553
    PubMedGoogle Scholar
  • 23 Steen V D, Costantino J P, Shapiro A P. et al . Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors.  Ann Intern Med. 1990;  113 352-357
    CrossrefPubMedGoogle Scholar
  • 24 Steen V D, Medsger T A. Changes in causes of death in systemic sclerosis, 1972 – 2002.  Ann Rheum Dis. 2007;  66 940-944
    CrossrefPubMedGoogle Scholar
  • 25 Steen V D, Lucas M, Fertig N. et al . Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.  J Rheumatol. 2007;  34 2230-2235
    PubMedGoogle Scholar
  • 26 Ferri C, Valentini G, Cozzi F. et al . Systemic sclerosis study group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serological features and survival in 1012 Italian patients.  Medicine. 2002;  81 139
    CrossrefPubMedGoogle Scholar
  • 27 Silver R M, Clements P J. Interstitial lung disease in systemic sclerosis: optimizing evaluation and management.  Scleroderma Care Research. 2003;  1 3-11
    PubMedGoogle Scholar
  • 28 D’Angelo W A, Fries J F, Masi A T. et al . Pathological observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls.  Am J Med. 1969;  46 428-440
    CrossrefPubMedGoogle Scholar
  • 29 Weaver A L, Divertie M B, Titus J L. Pulmonary scleroderma.  Dis Chest. 1968;  54 490-498
    CrossrefPubMedGoogle Scholar
  • 30 McNearney T A, Reveille J D, Fischbach M. et al . Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.  Arthritis & Rheumatism. 2007;  57 318-326
    CrossrefPubMedGoogle Scholar
  • 31 Mouthon L, Bérézne A, Brauner M. et al . [Interstitial lung disease in systemic sclerosis].  Rev Mal Respir. 2007;  24 1035-1046
    PubMedGoogle Scholar
  • 32 Hansell D M, Kerr I A. The role of high resolution computed tomography in the diagnosis of interstitial lung disease.  Thorax. 1991;  46 77-84
    CrossrefPubMedGoogle Scholar
  • 33 Desai S R, Veeraraghavan S, Hansell D M. et al . CT features of lung disease in systemic sclerosis: comparison with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.  Radiology. 2004;  232 560-567
    CrossrefPubMedGoogle Scholar
  • 34 Camiciottoli G, Orlandi I, Bartolucci M. et al . Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life.  Chest. 2007;  131 672-681
    CrossrefPubMedGoogle Scholar
  • 35 Bellia M, Cannizzaro F, Scichilone N. et al . HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities.  Radiol Med. 2009;  114 190-203
    CrossrefPubMedGoogle Scholar
  • 36 Clements P J, Goldin J G, Kleerup E C. et al . Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis.  Arthritis & Rheum. 2004;  50 1909-1917
    CrossrefPubMedGoogle Scholar
  • 37 Steen V D, Conte C, Owens G R. et al . Severe restrictive lung disease in systemic sclerosis.  Arthritis & Rheum. 1994;  37 1283-1289
    CrossrefPubMedGoogle Scholar
  • 38 Marcisz C E, Kucharz J, Brzezinska-Wcislo L. et al . Pulmonary functional abnormalities in asymptomatic patients with systemic sclerosis.  Eur J Intern Med. 2003;  14 162-165
    PubMedGoogle Scholar
  • 39 Buch M H, Denton C P, Furst D E. et al . Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test.  Ann Rheum Dis. 2007;  66 169-173
    PubMedGoogle Scholar
  • 40 Garin M C, Highland K B, Silver R M. et al . Limitations of the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.  J Rheumatol. 2009;  36 330-336
    CrossrefPubMedGoogle Scholar
  • 41 Ooi G C, Mok M Y, Tsang K W. et al . Interstitial lung disease in systemic sclerosis. An HRCT-clinical correlative study.  Acta Radiologica. 2003;  44 258-264
    CrossrefPubMedGoogle Scholar
  • 42 Goh N S, Desai S R, Veeraraghavan S. et al . Interstitial lung disease in systemic sclerosis: a simple staging system.  Am J Respir Crit Care Med. 2008;  177 1248-1254
    CrossrefPubMedGoogle Scholar
  • 43 Ravini M, Ferraro G, Barbieri B. et al . Changing strategies of lung biopsies in diffuse lung diseases: the impact of video-assisted thoracoscopy.  Eur Respir J. 1998;  11 99-103
    CrossrefPubMedGoogle Scholar
  • 44 Badesch D B, Abman S H, Simmoneau G. et al . Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.  Chest. 2007;  131 1917-1928
    CrossrefPubMedGoogle Scholar
  • 45 Hachulla E, Carpentier P, Gressin V. et al . Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study.  Rheumatology (Oxford). 2009;  48 304-208
    PubMedGoogle Scholar
  • 46 American Thoracic Society/European Respiratory Society . American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.  Am J Resp Crit Care Med. 2002;  165 277-304
    PubMedGoogle Scholar
  • 47 Bradley B, Branley H M, Egan J J. et al . Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.  Thorax. 2008;  63 (Suppl. 5) v1-58
    CrossrefPubMedGoogle Scholar
  • 48 Katzenstein A L, Fiorelli R F. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance.  Am J Surg Pathol. 1995;  18 136-147
    PubMedGoogle Scholar
  • 49 Kim D S, Yoo B, Lee J S. et al . The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia.  Sarcoidosis Vasc Diffuse Lung Dis. 2002;  19 121-127
    PubMedGoogle Scholar
  • 50 Bouros D, Wells A U, Nicholson A G. et al . Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.  Am J Respir Crit Care Med. 2002;  165 1581-1586
    CrossrefPubMedGoogle Scholar
  • 51 deCarvalho E F, Parra E R, deSouza R. et al . Arterial and interstitial remodelling processes in non-specific interstitial pneumonia: systemic sclerosis versus idiopathic.  Histopathology. 2008;  53 193-204
    PubMedGoogle Scholar
  • 52 Marie I, Dominique S, Levesque H. et al . Esophageal involvement and pulmonary manifestations in systemic sclerosis.  Arthritis Rheum. 2001;  45 346-354
    CrossrefPubMedGoogle Scholar
  • 53 Marie I, Ducrotte P, Denis P. et al . Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy.  Aliment Pharmacol Ther. 2006;  24 1593-1601
    CrossrefPubMedGoogle Scholar
  • 54 Savarino E, Bazzica M, Zentilin P. et al . Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring.  Am J Respir Crit Care Med. 2009;  179 408-413
    CrossrefPubMedGoogle Scholar
  • 55 Jain R, Shaul P W, Borok Z. et al . Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor mediated production of TGF-beta 1.  Am J Respir Cell Mol Biol. 2007;  37 38-47
    CrossrefPubMedGoogle Scholar
  • 56 Hagimoto N, Kuwano K, Nomoto Y. et al . Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice.  Am J Respir Cell Mol Biol. 1997;  16 91-101
    PubMedGoogle Scholar
  • 57 Hoyles R K, Khan K, Shiwen X. et al . Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model.  Arthritis Rheum. 2008;  58 1175-1188
    CrossrefPubMedGoogle Scholar
  • 58 Sonnylal S, Denton C P, Zheng B. et al . Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.  Arthritis Rheum. 2007;  56 334-344
    CrossrefPubMedGoogle Scholar
  • 59 Corrin B, Butcher D, McAnulty B J. et al . Immunohistochemical localization of TGF-β1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders.  Histopathology. 1994;  24 145-150
    CrossrefPubMedGoogle Scholar
  • 60 Branley H M, du Bois R M, Wells A U. et al . PET scanning of macrophages in patients with scleroderma fibrosing alveolitis.  Nucl Med Biol. 2008;  35 901-909
    CrossrefPubMedGoogle Scholar
  • 61 Gourh P, Tan F K, Assassi S. et al . Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.  Arthritis Rheum. 2006;  54 3945-3953
    CrossrefPubMedGoogle Scholar
  • 62 Mattuzzi S, Barbi S, Carletto A. et al . Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis.  J Rheumatol. 2007;  34 997-1004
    PubMedGoogle Scholar
  • 63 Fonseca C, Lindahl G E, Ponticos M. et al . A polymorphism in the CTGF promotor region associated with systemic sclerosis.  N Engl J Med. 2007;  357 1210-1220
    CrossrefPubMedGoogle Scholar
  • 64 Ates O, Müsellim B, Ongen G. et al . NRAMP1 (SLC11A1): A plausible candidate gene for systemic sclerosis (SSc) with interstitial lung involvement.  J Clin Immunol. 2008;  28 73-77
    PubMedGoogle Scholar
  • 65 Sumita Y, Sugiura T, Kawaguchi Y. et al . Genetic polymorphisms in the surfactant proteins in systemic sclerosis in Japanese: T/T genotype at 1580 C/T (Thr131Ile) in the SP-B gene reduces the risk of interstitial lung disease.  Rheumatology (Oxford). 2008;  47 289-291
    PubMedGoogle Scholar
  • 66 Dieudé P, Guedj W, Wipff J. et al . Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis.  Arthritis Rheum. 2009;  60 225-233
    CrossrefPubMedGoogle Scholar
  • 67 Renzoni E, Lympany P, Sestini P. et al . Distribution of novel polymorphisms of the interleukin-8 and cxc receptor 1 und 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis.  Arthritis & Rheumatism. 2000;  43 1633-1640
    CrossrefPubMedGoogle Scholar
  • 68 Ates O, Müsellim B, Ongen G. et al . Association between interleukin 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement.  Rheumatol Int. 2008;  28 1123-1126
    CrossrefPubMedGoogle Scholar
  • 69 Bredemeier M, Chies J A, Wieck A. et al . TCRBV20S1 and TCRBV3S1 Gene Segment Polymorphisms in Systemic Sclerosis.  J Rheumatol. 2008;  35 1058-1063
    PubMedGoogle Scholar
  • 70 Goh N S, Veeraraghavan S, Desai S R. et al . Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.  Arthritis Rheum. 2007;  56 2005-2012
    CrossrefPubMedGoogle Scholar
  • 71 Martinez J A, Nishimura C, Guatura S B. et al . Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis.  Rheumatol Int. 2001;  21 122-126
    CrossrefPubMedGoogle Scholar
  • 72 Andersen G N, Nilsson K, Pourazar J. et al . Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis.  Respir Med. 2007;  101 2199-2206
    CrossrefPubMedGoogle Scholar
  • 73 Scheja A, Larsen K, Todorova L. et al . BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis.  Eur Respir J. 2007;  29 446-452
    CrossrefPubMedGoogle Scholar
  • 74 Strange C, Bolster M B, Roth M D. et al . Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.  Am J Respir Crit Care Med. 2008;  177 91-98
    CrossrefPubMedGoogle Scholar
  • 75 Steen V D. The many faces of scleroderma.  Rheum Dis Clin North Am. 2008;  34 1-15; v.
    CrossrefPubMedGoogle Scholar
  • 76 Kuwana M, Medsger Jr T A, Wright T M. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.  J Clin Invest. 1995;  96 586-596
    CrossrefPubMedGoogle Scholar
  • 77 Ioannidis J P, Vlachoyiannopoulos P G, Haidich A B. et al . Mortality in systemic sclerosis: an international meta-analysis of individual patient data.  Am J Med. 2005;  118 2-10
    CrossrefPubMedGoogle Scholar
  • 78 Hu P Q, Hurwitz A A, Oppenheim J J. Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice.  J Rheumatol. 2007;  34 2243-2252
    PubMedGoogle Scholar
  • 79 Takahashi H, Kuroki Y, Tanaka H. et al . Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with systemic sclerosis.  Am J Respir Crit Care Med. 2000;  162 258-263
    CrossrefPubMedGoogle Scholar
  • 80 Yanaba K, Hasegawa M, Hamaguchi Y. et al . Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis.  Clin Exp Rheumatol. 2003;  21 429-436
    PubMedGoogle Scholar
  • 81 Kumánovics G, Minier T, Radics J. et al . Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.  Clin Exp Rheumatol. 2008;  26 414-420
    PubMedGoogle Scholar
  • 82 Hara T, Ogawa F, Yanaba K. et al . Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.  J Rheumatol. 2009;  36 99-105
    PubMedGoogle Scholar
  • 83 Nomura S, Inami N, Ozaki Y. et al . Significance of microparticles in progressive systemic sclerosis with interstitial pneumonia.  Platelets. 2008;  19 192-198
    CrossrefPubMedGoogle Scholar
  • 84 Malerba M, Radaeli A, Ragnoli B. et al . Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement.  Chest. 2007;  132 575-580
    CrossrefPubMedGoogle Scholar
  • 85 Tiev K P, Cabane J, Aubourg F. et al . Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide.  Eur Respir J. 2007;  30 26-30
    CrossrefPubMedGoogle Scholar
  • 86 Tashkin D P, Elashoff R, Clements P J. et al . Cyclophosphamide versus placebo in scleroderma lung disease.  N Engl J Med. 2006;  354 2655-2666
    CrossrefPubMedGoogle Scholar
  • 87 Tashkin D P, Elashoff R, Clements P J. et al . Effects of 1-year treatment with cyclophosphamid on outcomes at 2 years in scleroderma lung disease.  Am J Respir Crit Care Med. 2007;  176 1026-1034
    CrossrefPubMedGoogle Scholar
  • 88 Tzelepis G E, Plastiras S C, Karadimitrakis S P. et al . Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.  Clin Exp Rheumatol. 2007;  25 734-739
    PubMedGoogle Scholar
  • 89 Hoyles R K, Ross W E, Wellsbury J. et al . A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous Cyclophosphamide followed by oral Azathioprine for the treatment of pulmonary fibrosis in scleroderma.  Arthritis & Rheumatism. 2006;  54 3962-3970
    CrossrefPubMedGoogle Scholar
  • 90 Bérézne A, Ranque B, Valeyre D. et al . Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.  J Rheumatol. 2008;  35 1064-1072
    PubMedGoogle Scholar
  • 91 Dheda K, Lalloo U G, Casim B. et al . Experience with azathioprine in systemic sclerosis associated with interstitial lung disease.  Clin Rheumatol. 2004;  23 306-309
    PubMedGoogle Scholar
  • 92 Sabnani I, Zucker M J, Rosenstein E D. et al . A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamid.  Rheumatology (Oxford). 2009;  48 49-52
    CrossrefPubMedGoogle Scholar
  • 93 Paniagua R T, Sharpe O, Ho P P. et al . Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.  J Clin Invest. 2006;  116 2633-2642
    PubMedGoogle Scholar
  • 94 Baroni S S, Santillo M, Bevilacqua F. et al . Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.  N Engl J Med. 2006;  354 2667-2676
    CrossrefPubMedGoogle Scholar
  • 95 Kallenberg C G, Jansen H M, Elema J D. et al . Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage.  Chest. 1984;  86 489-492
    CrossrefPubMedGoogle Scholar
  • 96 Krishna Sumanth M, Sharma V K, Khaitan B K. et al . Evaluation of oral methotrexate in the treatment of systemic sclerosis.  International Journal of Dermatology. 2007;  46 218-223
    PubMedGoogle Scholar
  • 97 Imokawa S, Colby T, Leslie K O. et al . Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.  Eur Respir J. 2000;  15 373-381
    CrossrefPubMedGoogle Scholar
  • 98 Au K, Khanna D, Clements P J. et al . Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.  Curr Rheumatol Rep. 2009;  11 111-119
    CrossrefPubMedGoogle Scholar
  • 99 Nash R A, McSweeney P A, Crofford L J. et al . High-dose immunosuppressive therapy (HDIT) and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.  Blood. 2007;  110 1388-1396
    CrossrefPubMedGoogle Scholar
  • 100 Shiratsuchi M, Motomura S, Abe Y. et al . Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis.  Clin Rheumatol. 2008;  27 1207-1209
    CrossrefPubMedGoogle Scholar
  • 101 Williams T J, Wilson J W. Challenges in pulmonary fibrosis: 7-novel therapies and lung transplantation.  Thorax. 2008;  63 277-284
    CrossrefPubMedGoogle Scholar
  • 102 Schachna L, Medsger Jr T A, Dauber J H. et al . Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.  Arthritis Rheum. 2006;  54 3954-3961
    CrossrefPubMedGoogle Scholar
  • 103 Galiè N, Torbicki A, Barst R. et al . Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
    CrossrefPubMedGoogle Scholar
  • 104 Olschewski H, Hoeper M M, Borst M M. et al . [Diagnosis and therapy of chronic pulmonary hypertension].  Pneumologie. 2006;  60 749-771
    Article in Thieme ConnectPubMedGoogle Scholar
  • 105 Hachulla E, Gressin V, Guillevin . et al . Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.  Arthritis Rheum. 2005;  52 3792-3800
    CrossrefPubMedGoogle Scholar
  • 106 Murakoshi N, Miyauchi T, Kakinuma Y. et al . Vascular endothelin-B receptor system in vivo plays a favourable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice.  Circulation. 2002;  106 1991-1998
    CrossrefPubMedGoogle Scholar
  • 107 Kulasekaren P, Scavone C A, Rogers D S. et al . Endothelin-1 and TGF-{beta} independently induce fibroblast resistance to apoptosis via AKT activation.  Am J Respir Cell Mol Biol. 2009;  (im Druck)
    PubMedGoogle Scholar
  • 108 King Jr T E, Behr J, Brown K K. et al . BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 2008;  177 75-81
    CrossrefPubMedGoogle Scholar
  • 109 Seibold J R, Black C M, Denton C P. et al . Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): the BUILD-2 Study [abstract].  Proc Am Thorac Soc. 2006;  3 A243
    PubMedGoogle Scholar
  • 110 D’Alonzo G E, Barst R J, Ayres S M. et al . Survival in patients with primary pulmonary hypertension. Results form a national prospective registry.  Ann Intern Med. 1991;  115 343-349
    PubMedGoogle Scholar
  • 111 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
    CrossrefPubMedGoogle Scholar
  • 112 McLaughlin V V. Survival in patients with pulmonary hypertension treated with first-line bosentan.  Eur J Clin Invest. 2006;  36 (Suppl. 3) 10-15
    CrossrefPubMedGoogle Scholar
  • 113 Barst R J, Langleben D, Badesch D. et al . Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.  J Am Coll Cardiol. 2006;  47 2049-2056
    CrossrefPubMedGoogle Scholar
  • 114 Girgis R E, Frost A E, Hill N S. et al . Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.  Ann Rheum Dis. 2007;  66 1467-1472
    CrossrefPubMedGoogle Scholar
  • 115 Benza R L, Barst R J, Galié N. et al . Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.  Chest. 2008;  134 775-782
    CrossrefPubMedGoogle Scholar
  • 116 Galiè N, Olschewski H, Oudiz R J. et al . Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.  Circulation. 2008;  117 3010-3019
    CrossrefPubMedGoogle Scholar
  • 117 Badesch D B, Hill N S, Burgess G. et al . Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.  J Rheumatol. 2007;  34 2417-2422
    PubMedGoogle Scholar
  • 118 Galiè N, Rubin L J, Hoeper M M. et al . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.  Lancet. 2008;  371 2093-2100
    CrossrefPubMedGoogle Scholar
  • 119 Olschewski H, Simonneau G, Galie N. et al . Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
    CrossrefPubMedGoogle Scholar
  • 120 Hoeper M M, Markevych I, Spiekerkoetter E. et al . Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.  Eur Respir J. 2005;  26 858-863
    CrossrefPubMedGoogle Scholar
  • 121 Porhownik N R, Al-Sharif H, Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.  Can Respir J. 2008;  15 427-430
    PubMedGoogle Scholar
  • 122 Dimitroulas T, Giannakoulas G, Karvounis H. et al . N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.  Clin Rheumatol. 2008;  27 655-658
    CrossrefPubMedGoogle Scholar
  • 123 Trad S, Amoura Z, Beigelman C. et al . Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.  Arthritis Rheum. 2006;  54 184-191
    CrossrefPubMedGoogle Scholar
  • 124 Mathai S C, Hummers L K, Champion H C. et al . Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.  Arthritis Rheum. 2009;  60 569-577
    CrossrefPubMedGoogle Scholar
  • 125 Girgis R E, Mathai S C, Krishnan J A. et al . Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.  J Heart Lung Transplant. 2005;  24 1626-1631
    CrossrefPubMedGoogle Scholar
  • 126 Huez S, Roufosse F, Vachiéry J-L. et al . Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension?.  Eur Respir J. 2007;  30 928-936
    CrossrefPubMedGoogle Scholar
  • 127 Steen V D, Chou M, Shanmugam V. et al . Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis.  Chest. 2008;  134 146-151
    CrossrefPubMedGoogle Scholar
  • 128 Hanitsch L G, Burmester G-R, Witt C. et al . Skin sclerosis is only of limited value to identify SSc patients with severe manifestations – an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.  Rheumatology (Oxford). 2009;  48 70-73
    PubMedGoogle Scholar
  • 129 Denton C P, Merkel P A, Furst D E. et al . Recombinant human anti-transforming growth factor beta1 antibody in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.  Arthritis Rheum. 2007;  56 323-333
    CrossrefPubMedGoogle Scholar
  • 130 Hancock A, Armstrong L, Gama R. et al . Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung.  Am J Respir Cell Mol Biol. 1998;  18 60-65
    PubMedGoogle Scholar
  • 131 Granel B, Allanore Y, Chevillard C. et al . IL13RA2 gene polymorphisms are associated with systemic sclerosis.  J Rheumatol. 2006;  33 2015-2019
    PubMedGoogle Scholar

Dr. Heiko Knoop

Medizinische Klinik III – Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin
Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH
Klinikum der Ruhr-Universität Bochum

Bürkle-de-la-Camp-Platz 1
44789 Bochum

Email: Heiko.Knoop@ruhr-uni-bochum.de